Literature DB >> 9355205

Seronegative spondyloarthropathy in familial Mediterranean fever.

P Langevitz1, A Livneh, D Zemer, J Shemer, M Pras.   

Abstract

To define a possible association between familial Mediterranean fever (FMF) and seronegative spondyloarthropathy (SNSA) and to study features of SNSA in FMF patients, we screened for the presence and manifestations of SNSA in 3,000 FMF patients attending the National Center for FMF in our institution. This population included 160 patients with chronic arthritis, most who suffered from SNSA. Patients were considered to suffer from SNSA if they had chronic arthritis, inflammatory back/neck pain, and sacroiliitis. Patients who had other diseases associated with SNSA were excluded. Eleven patients, nine men and two women, with chronic monoarthritis or oligoarthritis, grade 2 (four patients) or grades 3 to 4 (seven patients), sacroiliitis, and inflammatory back pain met the criteria for diagnosis of SNSA of FMF. These patients were rheumatoid factor (RF) and HLA-B27 negative. In seven patients, spondyloarthropathy developed while they received colchicine, and in four before colchicine. Most patients responded to treatment with nonsteroidal antiinflammatory drugs, but three required second-line agents. These findings suggest that SNSA is one of the musculoskeletal manifestations of FMF that may occur despite colchicine therapy and requires specific treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355205     DOI: 10.1016/s0049-0172(97)80007-8

Source DB:  PubMed          Journal:  Semin Arthritis Rheum        ISSN: 0049-0172            Impact factor:   5.532


  25 in total

Review 1.  The myths we believed in familial Mediterranean fever: what have we learned in the past years?

Authors:  Seza Ozen; Ezgi Deniz Batu
Journal:  Semin Immunopathol       Date:  2015-04-02       Impact factor: 9.623

2.  Osteopoikilosis coexistent with ankylosing spondylitis and familial Mediterranean fever.

Authors:  Ismail Sari; Ismail Simsek; Inanc Guvenc; Hatice Tuba Sanal; Hakan Erdem; Salih Pay; Ayhan Dinc
Journal:  Rheumatol Int       Date:  2008-08-12       Impact factor: 2.631

3.  M694V mutation may have a role in susceptibility to ankylosing spondylitis.

Authors:  Servet Akar; Merih Birlik; Ismail Sari; Fatos Onen; Nurullah Akkoc
Journal:  Rheumatol Int       Date:  2009-01-17       Impact factor: 2.631

4.  Sacroiliitis in familial Mediterranean fever and seronegative spondyloarthropathy: importance of differential diagnosis.

Authors:  Birol Balaban; Evren Yasar; Ahmet Ozgul; Kemal Dincer; Tunc Alp Kalyon
Journal:  Rheumatol Int       Date:  2005-02-12       Impact factor: 2.631

Review 5.  Familial Mediterranean fever and ankylosing spondylitis in a patient with juvenile idiopathic arthritis: A case report and review of the literature.

Authors:  Işik Keleş; Gülümser Aydin; Aliye Tosun; Elem Inal; Hatice Keleş; Sevim Orkun
Journal:  Rheumatol Int       Date:  2005-11-24       Impact factor: 2.631

6.  The expanded clinical spectrum of familial Mediterranean fever.

Authors:  Z Birsin Ozçakar; Fatoş Yalçinkaya; Selçuk Yüksel; Mesiha Ekim
Journal:  Clin Rheumatol       Date:  2006-10-24       Impact factor: 2.980

Review 7.  Familial Mediterranean fever: An updated review.

Authors:  İsmail Sarı; Merih Birlik; Timuçin Kasifoğlu
Journal:  Eur J Rheumatol       Date:  2014-03-01

8.  Familial Mediterranean fever responds well to infliximab: single case experience.

Authors:  Salih Ozgocmen; Levent Ozçakar; Ozge Ardicoglu; Ercan Kocakoc; Arzu Kaya; Adem Kiris
Journal:  Clin Rheumatol       Date:  2005-09-20       Impact factor: 2.980

9.  Coexistence of familial Mediterranean fever with sacroiliitis and Behçet's disease: a rare occurrence.

Authors:  M Birlik; M Tunca; N Hizli; M Soytürk; Y Yeniçerioğlu; M A Ozcan; O El
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

10.  The frequency of sacroiliitis in familial Mediterranean fever and the role of HLA-B27 and MEFV mutations in the development of sacroiliitis.

Authors:  Timuçin Kaşifoğlu; Cüneyt Calişir; Döndü U Cansu; Cengiz Korkmaz
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.